Corcept Therapeutics (CORT) Common Equity (2010 - 2026)

Corcept Therapeutics (CORT) has 17 years of Common Equity data on file, last reported at $638.0 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 6.63% year-over-year to $638.0 million; the trailing twelve-month figure through Mar 2026 stood at $638.0 million (down 6.63% YoY), and the FY2025 full-year result was $647.8 million, down 4.68% from the prior year.
• Common Equity declined to $638.0 million in Q1 2026, from $647.8 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $683.3 million in Q1 2025 to a low of $407.8 million in Q1 2022.
• A 5-year average of $555.5 million and a median of $547.9 million in 2024 frame the typical range for Common Equity.
• Across the five-year window, Common Equity retreated 20.16% in 2022 and jumped 41.42% in 2024, its largest moves.
• Tracing CORT's Common Equity over 5 years: stood at $501.8 million in 2022, then increased by 0.97% to $506.7 million in 2023, then jumped by 34.12% to $679.6 million in 2024, then slipped by 4.68% to $647.8 million in 2025, then dropped by 1.52% to $638.0 million in 2026.
• Business Quant data shows CORT's Common Equity at $638.0 million in Q1 2026, $647.8 million in Q4 2025, and $631.9 million in Q3 2025.